Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.

Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D'Souza DC.

Biol Psychiatry. 2016 Jun 15;79(12):997-1005. doi: 10.1016/j.biopsych.2015.08.021. Epub 2015 Aug 29.

PMID:
26432420
2.

Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.

Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A, Taurisano P, Romano R, Masellis R, Blasi G, Morgan C, Aitchison K, Mondelli V, Luzi S, Kolliakou A, David A, Murray RM, Bertolino A, Di Forti M.

Schizophr Bull. 2015 Sep;41(5):1171-82. doi: 10.1093/schbul/sbv032. Epub 2015 Mar 31.

3.

The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study.

Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS.

Psychol Med. 2015 Jan;45(2):407-14. doi: 10.1017/S0033291714001524. Epub 2014 Jul 3.

4.

Gone to Pot - A Review of the Association between Cannabis and Psychosis.

Radhakrishnan R, Wilkinson ST, D'Souza DC.

Front Psychiatry. 2014 May 22;5:54. doi: 10.3389/fpsyt.2014.00054. eCollection 2014. Review.

5.

Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada.

Harris GE, Dupuis L, Mugford GJ, Johnston L, Haase D, Page G, Haldane H, Harris N, Midodzi WK, Dow G.

Can J Infect Dis Med Microbiol. 2014 Spring;25(1):e1-7.

6.

Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.

Seillier A, Martinez AA, Giuffrida A.

Neuropsychopharmacology. 2013 Aug;38(9):1816-24. doi: 10.1038/npp.2013.81. Epub 2013 Apr 5.

7.

MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse.

Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S, Andreasen NC, Ho BC.

Psychol Med. 2013 Mar;43(3):619-31. doi: 10.1017/S0033291712001559. Epub 2012 Jul 31.

8.

Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia.

Caballero A, Tseng KY.

Front Pharmacol. 2012 May 28;3:101. doi: 10.3389/fphar.2012.00101. eCollection 2012.

9.

New insights on endocannabinoid transmission in psychomotor disorders.

Giuffrida A, Seillier A.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):51-8. doi: 10.1016/j.pnpbp.2012.04.002. Epub 2012 Apr 10. Review.

10.

Maternal deprivation and adolescent cannabinoid exposure impact hippocampal astrocytes, CB1 receptors and brain-derived neurotrophic factor in a sexually dimorphic fashion.

López-Gallardo M, López-Rodríguez AB, Llorente-Berzal Á, Rotllant D, Mackie K, Armario A, Nadal R, Viveros MP.

Neuroscience. 2012 Mar 1;204:90-103. doi: 10.1016/j.neuroscience.2011.09.063. Epub 2011 Oct 6.

11.

Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Ho BC, Wassink TH, Ziebell S, Andreasen NC.

Schizophr Res. 2011 May;128(1-3):66-75. doi: 10.1016/j.schres.2011.02.021. Epub 2011 Mar 21.

12.

Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Pacher P, Mechoulam R.

Prog Lipid Res. 2011 Apr;50(2):193-211. doi: 10.1016/j.plipres.2011.01.001. Epub 2011 Feb 2. Review.

13.

Heterogeneity in the composition of marijuana seized in California.

Burgdorf JR, Kilmer B, Pacula RL.

Drug Alcohol Depend. 2011 Aug 1;117(1):59-61. doi: 10.1016/j.drugalcdep.2010.11.031. Epub 2011 Feb 1.

14.

Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms.

Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R, Holt D, Wilson D, Sumich A, McGuire P, Murray RM, Kapur S, Ffytche DH.

Neuropsychopharmacology. 2011 Mar;36(4):827-36. doi: 10.1038/npp.2010.222. Epub 2010 Dec 8.

15.

Cannabis users differ from non-users on measures of personality and schizotypy.

Fridberg DJ, Vollmer JM, O'Donnell BF, Skosnik PD.

Psychiatry Res. 2011 Mar 30;186(1):46-52. doi: 10.1016/j.psychres.2010.07.035.

16.

Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex.

Chiu CQ, Puente N, Grandes P, Castillo PE.

J Neurosci. 2010 May 26;30(21):7236-48. doi: 10.1523/JNEUROSCI.0736-10.2010.

17.

Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.

Greineisen WE, Turner H.

Int Immunopharmacol. 2010 May;10(5):547-55. doi: 10.1016/j.intimp.2010.02.012. Epub 2010 Feb 25. Review.

18.

Cannabis-induced bipolar disorder with psychotic features: a case report.

Khan MA, Akella S.

Psychiatry (Edgmont). 2009 Dec;6(12):44-8.

Items per page

Supplemental Content

Write to the Help Desk